Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Poly(ADP-ribose) Polymerase Inhibitor”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Testing effectiveness (Phase 2)Looking for participantsNCT07446855
What this trial is testing

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Who this might be right for
Solid Tumours
AstraZeneca 180
Large-scale testing (Phase 3)Ended earlyNCT02470585
What this trial is testing

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerOvarian Neoplasm
AbbVie 1,140
Testing effectiveness (Phase 2)Active Not RecruitingNCT06433219
What this trial is testing

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Who this might be right for
Ovarian Cancer
EMD Serono Research & Development Institute, Inc. 63
Early research (Phase 1)Study completedNCT00994071
What this trial is testing

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Who this might be right for
MedulloblastomaPontine GliomaEpendymoma+2 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)Looking for participantsNCT05417594
What this trial is testing

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Malignancies
AstraZeneca 695
Testing effectiveness (Phase 2)Study completedNCT01618136
What this trial is testing

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Who this might be right for
Malignant Solid TumourOvarian CancerTriple Negative Breast Cancer+2 more
Eisai Limited 41
Early research (Phase 1)Looking for participantsNCT06121557
What this trial is testing

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 24
Testing effectiveness (Phase 2)Study completedNCT01051596
What this trial is testing

ABT-888 in Combination With Temozolomide for Colorectal Cancer

Who this might be right for
Colorectal Cancer
Georgetown University 75
Testing effectiveness (Phase 2)Study completedNCT00271765
What this trial is testing

INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

Who this might be right for
Acute Myocardial Infarction
Inotek Pharmaceuticals Corporation 40
Early research (Phase 1)Ended earlyNCT01127178
What this trial is testing

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumors
Eisai Inc. 12
Early research (Phase 1)Study completedNCT00946335
What this trial is testing

ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors

Who this might be right for
Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus Tumor+25 more
National Cancer Institute (NCI) 31
Early research (Phase 1)Ended earlyNCT02500901
What this trial is testing

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Prostate Cancer
Paul Mathew, MD 2
Not applicableUnknownNCT05044091
What this trial is testing

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Who this might be right for
Ovarian CancerHRDPARP Inhibitor
Xiaoxiang Chen 100
Testing effectiveness (Phase 2)Ended earlyNCT05286827
What this trial is testing

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Who this might be right for
Pancreatic Acinar Cell Carcinoma
National Cancer Institute (NCI) 5
Large-scale testing (Phase 3)Looking for participantsNCT07472140
What this trial is testing

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancersPrimary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre 120
Testing effectiveness (Phase 2)Study completedNCT04740190
What this trial is testing

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

Who this might be right for
Recurrent GliomaRecurrent GlioblastomaPoly ADP Ribose Polymerase (PARP) Inhibitor+2 more
The University of Hong Kong 33
Early research (Phase 1)Ended earlyNCT01226901
What this trial is testing

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

Who this might be right for
NeoplasmsSolid Tumors
Merck Sharp & Dohme LLC 3
Early research (Phase 1)Ended earlyNCT03944902
What this trial is testing

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

Who this might be right for
Ovarian CancerResistant BRCA Wild-Type Ovarian Cancer
University of Alabama at Birmingham 1
Testing effectiveness (Phase 2)UnknownNCT03016338
What this trial is testing

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
University Health Network, Toronto 51
Testing effectiveness (Phase 2)Ended earlyNCT01605162
What this trial is testing

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Who this might be right for
Wild Type BRAF Stage IV MelanomaUnresectable Stage III Melanoma
Eisai Inc. 8
Load More Results